We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

171 hedge funds and large institutions have $272M invested in Heron Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 66 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,671% more call options, than puts

Call options by funds: $3.28M | Put options by funds: $87K

113% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 31

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

4% more funds holding

Funds holding: 164 → 171 (+7)

4.26% more ownership

Funds ownership: 81.91% → 86.17% (+4.3%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1% less capital invested

Capital invested by funds: $274M → $272M (-$2.36M)

Holders
171
Holders Change
+7
Holders Change %
+4.27%
% of All Funds
2.25%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
25
Increased
66
Reduced
31
Closed
17
Calls
$3.28M
Puts
$87K
Net Calls
+$3.19M
Net Calls Change
-$845K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$6.18M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.51M
3
Marshall Wace
Marshall Wace
United Kingdom
+$3.35M
4
BlackRock
BlackRock
New York
+$3.14M
5
Morgan Stanley
Morgan Stanley
New York
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.5M
2
Millennium Management
Millennium Management
New York
-$1.84M
3
OCM
Orchard Capital Management
Illinois
-$1.58M
4
EI
EAM Investors
California
-$768K
5
CC
Clearline Capital
New York
-$414K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.16M +$29.9K +14,632 +1%
JP Morgan Chase
27
JP Morgan Chase
New York
$1.97M +$524K +256,637 +37%
Two Sigma Investments
28
Two Sigma Investments
New York
$1.95M -$230K -112,399 -11%
CC
29
Clearline Capital
New York
$1.77M -$414K -202,745 -19%
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$1.7M +$1.68M +820,504 New
BCM
31
Bridgeway Capital Management
Texas
$1.45M – – –
JFG
32
Jefferies Financial Group
New York
$1.38M +$703K +344,200 +107%
OCM
33
Orchard Capital Management
Illinois
$1.37M -$1.58M -771,825 -54%
SCM
34
Stonepine Capital Management
Oregon
$1.36M -$283K -138,720 -17%
CM
35
CM Management
Florida
$1.24M – – –
RB
36
Richmond Brothers
Michigan
$1.15M +$19.5K +9,568 +2%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.1M -$277K -135,400 -20%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.02M +$11.9K +5,841 +1%
Millennium Management
39
Millennium Management
New York
$1.02M -$1.84M -902,948 -65%
NAM
40
Nexpoint Asset Management
Texas
$985K – – –
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$894K +$475K +232,655 +117%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$832K +$151K +73,769 +22%
TD Asset Management
43
TD Asset Management
Ontario, Canada
$817K – – –
N
44
Nuveen
North Carolina
$718K +$67K +32,790 +10%
Jane Street
45
Jane Street
New York
$686K +$644K +315,358 +1,968%
Barclays
46
Barclays
United Kingdom
$665K +$284K +138,878 +76%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$633K +$65.1K +31,898 +12%
Walleye Capital
48
Walleye Capital
New York
$621K +$612K +299,790 New
GCP
49
GSA Capital Partners
United Kingdom
$615K +$607K +297,321 New
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$551K +$405K +198,325 +293%
1
2
3 4 5

HRTX Hedge Fund Activity: Q2 2025 in Review

171 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2025, worth a combined $272M — down 0.86% from $274M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HRTX positions and 17 closed out — a net gain of 8 holders — while 66 added to existing stakes and 31 trimmed.

The largest buyer was UBS Group, adding an estimated $6.18M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $10.5M sold.

  • 171 institutional investors held Heron Therapeutics (HRTX) as of Q2 2025, up from 164 in Q1 2025.
  • Funds reported $272M of Heron Therapeutics stock for Q2 2025, down 0.86% quarter-over-quarter.
  • 25 funds opened new Heron Therapeutics positions in Q2 2025 and 17 closed out, a net change of +8 holders.
  • The largest Heron Therapeutics buyer in Q2 2025 was UBS Group, an estimated $6.18M added.
  • The largest Heron Therapeutics seller in Q2 2025 was Point72 Asset Management, an estimated $10.5M sold.

Based on aggregated 13F filings for Q2 2025.